GMDC’s Blough passes away at 58
COLORADO SPRINGS, Colo. GMDC on Thursday announced that Doug Blough, longtime director of communications for the association, passed away on March 22 at the age of 58 after a battle against pancreatic cancer.
“Doug made huge contributions to GMDC and its success over the years and he’ll be missed by all of us privileged to have worked with him,” stated David McConnell, GMDC president and chief executive officer. “He fought against this insidious disease and to the very end maintained the sense of dignity, kindness and caring for others that were at the core of who he was and how he’ll be remembered by all of us who were privileged to have known him.”
A resident of Colorado Springs since 1975, Blough’s relationship with GMDC spanned more than two decades as he served as an outside vendor providing visual communications services until he joined the staff management team in December of 1999. His tenure as a GMDC employee continued until the end of 2005 when he retired to spend more time with his wife Linda and pursue his passion for fine art digital imagery.
Even after his retirement from staff duty he was retained as a contractor who continued to manage GMDC’s creative and communication activities as well as serving as the Association’s liaison interfacing with the trade press and managing its public relations programs.
“Throughout his long tenure with GMDC Doug played a significant role in creating and managing the GMDC brand and was beloved in the industry as a person who always had a smile and a good word to say to anyone he ever encountered,” the association stated.
“Doug talked to me just a week ago about his anticipated passing with a sense of calm that amazed me and he actually played a big role in the planning of his funeral,” McConnell said. The funeral is being held Friday, March 28. McConnell is delivering the eulogy. “In these conversations and the planning process with [his wilfe] Linda he was consistent in stressing that it was very important that his passing be a celebration of his ife and who he was … not a time of sadness.”
The family has asked that in lieu of flowers donations be made to:
The Blough Children Educational Fundc/o US Bank6 South Tejon StreetColorado Springs, Colorado 80903Attention: L. Specht
Sugar may be helpful for those with diabetes and obesity
BALTIMORE Researchers have found a new treatment that may be helpful in aiding those with diabetes and obesity, and it is most unusually a sugar.
The sugar is known as tagatose, which, according to published reports, is used in Europe to sweeten candy or orange juice. It is a naturally occurring version of fructose and is derived from the dairy byproduct whey. Tagatose has been shown to stop blood sugar spiking and is currently undergoing a one-year clinical trial to see if is, in fact, helpful in managing diabetes and weight-loss.
According to the American Diabetes Association, about 20.8 million people are diabetic and 9 out of 10 diabetics with Type 2 are overweight. Many researchers, such as Phillip Levin, an endocrinologist and director of diabetes center at Mercy, hope that tagatose can become a diet drug for patients experiencing obesity, one of the leading causes of diabetes. According to Levin, “Tagatose could be another tool for damage control. A lot of dealing with Type 2 diabetes is damage control.”
Other studies have shown that tagatose, if ingested before meals, would stop the rise in blood sugar, because it is absorbed poorly and therefore affects the way the sugar is stored. According to published reports, tagatose is said to be possibly the only diabetes drug that could raise good cholesterol and act as a cell-protecting antioxidant.
FDA to take a closer look at Singulair
WASHINGTON The Food and Drug Administration has warned health care professionals that it is investigating possible side effects in the asthma drug Singulair.
Possible side effects of the drug, a Merck product, include behavior/mood changes, suicidality and suicide.
The agency will need up to nine months to complete ongoing evaluations about the safety of the drug.
“Patients should not stop taking Singulair before talking to their doctor if they have questions about this new information,” the FDA said. “Until further information is available, healthcare professionals and caregivers should monitor patients taking Singulair for suicidality and changes in behavior and mood.”